NCT04176757View on ClinicalTrials.gov

A Study of ZN-c5 in Participants With Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 3, 2020

Primary Completion Date

April 27, 2021

Study Completion Date

May 25, 2021

Conditions
Breast Cancer
Interventions
DRUG

ZN-c5

ZN-c5 study drug to be administered orally daily

Trial Locations (10)

2109

Site 9, Sydney

2170

Site 11, Liverpool

3121

Site 8, Richmond

4870

Site 10, Cairns

10032

Site 2, New York

37240

Site 4, Nashville

77030

Site 1, Houston

78000

Site 7, Banja Luka

85719

Site 3, Tucson

98109

Site 5, Seattle

All Listed Sponsors
lead

Zeno Alpha Inc.

INDUSTRY

NCT04176757 - A Study of ZN-c5 in Participants With Breast Cancer | Biotech Hunter | Biotech Hunter